Market closed
Dyne Therapeutics/$DYN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Dyne Therapeutics
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
Ticker
$DYN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
173
Website
DYN Metrics
BasicAdvanced
$2.4B
Market cap
-
P/E ratio
-$3.51
EPS
1.10
Beta
-
Dividend rate
Price and volume
Market cap
$2.4B
Beta
1.1
52-week high
$47.45
52-week low
$11.93
Average daily volume
1M
Financial strength
Current ratio
17.022
Quick ratio
16.728
Long term debt to equity
2.841
Total debt to equity
3.523
Management effectiveness
Return on assets (TTM)
-40.35%
Return on equity (TTM)
-68.69%
Valuation
Price to book
3.46
Price to tangible book (TTM)
3.46
Price to free cash flow (TTM)
-8.243
Growth
Earnings per share change (TTM)
-3.06%
3-year earnings per share growth (CAGR)
11.10%
What the Analysts think about DYN
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Dyne Therapeutics stock.
DYN Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DYN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DYN News
AllArticlesVideos
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases
Seeking Alpha·1 month ago
Dyne Therapeutics to Present at Upcoming Investor Conferences
GlobeNewsWire·1 month ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Dyne Therapeutics stock?
Dyne Therapeutics (DYN) has a market cap of $2.4B as of December 23, 2024.
What is the P/E ratio for Dyne Therapeutics stock?
The price to earnings (P/E) ratio for Dyne Therapeutics (DYN) stock is 0 as of December 23, 2024.
Does Dyne Therapeutics stock pay dividends?
No, Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders as of December 23, 2024.
When is the next Dyne Therapeutics dividend payment date?
Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders.
What is the beta indicator for Dyne Therapeutics?
Dyne Therapeutics (DYN) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.